CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background—: Statins (HMG-CoA reductase inhibitors) are the most prescribed class of lipid-lowering drugs for the treatment and prevention of cardiovascular disease. Creatine kinase (CK) is a commonly used biomarker to assist in the diagnosis of statin-induced myotoxicity but the normal range of CK concentrations is wide, which limits its use as a diagnostic biomarker. Methods and Results—: We conducted a genome-wide association study of serum CK levels in 3412 statin users. Patients were recruited in Quebec, Canada, and genotyped on Illumina Human610-Quad and an iSelect panel enriched for lipid homeostasis, hypertension, and drug metabolism genes. We found a strong association signal between serum levels of CK and the muscle CK ( CKM ) gene (rs11559024: P =3.69×10 −16 ; R 2 =0.02) and with the leukocyte immunoglobulin-like receptor subfamily B member 5 ( LILRB5 ) gene (rs2361797: P =1.96×10 −10 ; R 2 =0.01). Genetic variants in those 2 genes were independently associated with CK levels in statin users. Results were successfully replicated in 5330 participants from the Montreal Heart Institute Biobank in statin users for CKM (rs11559024: P =4.32×10 −16 ; R 2 =0.02) and LILRB5 (rs12975366 P =4.45×10 −10 ; R 2 =0.01) and statin nonusers ( P =4.08×10 −7 , R 2 =0.01; P =3.17×10 −9 , R 2 =0.02, respectively). Conclusions—: This is the first genome-wide study to report on the underlying genetic determinants of CK variation in a population of statin users. We found statistically significant association for variants in the CKM and LILRB5 genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towards a knowledge-based Human Protein Atlas
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1210-1248 · Cited by 2,440
Systematic identification of trans eQTLs as putative drivers of known disease associations
Westra, H.-J., Peters, M. J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J., Christiansen, M. W., Fairfax, B. P., Schramm, K., Powell, J. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2756 · Cited by 1,658
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · cited 1×
“5% in the Prediction of Muscular Risk in Observational Conditions (PRIMO) study, an observational study in an unselected hyperlipidemic patient population receiving high-dose statins.(7) Many patients stop statin therapy for aches and pains that are mistakenly thought to be related to their medication, which underscor…”
BackgroundACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Paxdb, a database of protein abundance averages across all three domains of life
Wang, M., Weiss, M., Simonovic, M., Haertinger, G., Schrimpf, S. P., Hengartner, M. O., & von Mering, C. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o111.014704 · Cited by 466 · cited 1×
“Mass spectrometry has detected the protein in plasma, liver, and aorta and this plasmatic protein has been ascertained in the HUPO plasma proteome project.(27,28) Furthermore, we could not find evidence of LILRB5 modulation by statins.”
BackgroundMcKenney, J. M., Davidson, M. H., Jacobson, T. A., & Guyton, J. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.030 · Cited by 431
Panagiotou, O. A., Ioannidis, J. P. A., & for the Genome-Wide Significance Project (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr178 · Cited by 286
AMELINK, G. J., KOOT, R. W., ERICH, W. B. M., VAN GIJN, J., & BÄR, P. R. (1990) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1990.tb08823.x · Cited by 109
Cited by
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Hirayasu, K., & Arase, H. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.64 · Cited by 129
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Deng, M., Chen, H., Liu, X., Huang, R., He, Y., Yoo, B., Xie, J., John, S., Zhang, N., An, Z., et al. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab002 · Cited by 53
Bossé, S., Stalder, T., & D'Antono, B. (2018) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000569 · Cited by 33
Metadata
- Authors
- Dubé, M.-P., Zetler, R., Barhdadi, A., Brown, A. M. K., Mongrain, I., Normand, V., Laplante, N., Asselin, G., Zada, Y. F., Provost, S., Bergeron, J., Kouz, S., Dufour, R., Diaz, A., de Denus, S., Turgeon, J., Rhéaume, E., Phillips, M. S., & Tardif, J.-C.
- Venue
- Circulation: Cardiovascular Genetics
- Published
- 2014-12
- Volume
- 7
- Issue
- 6
- Pages
- 880-886
- ISSN
- 1942-325X (ISSN-L)
- 1942-3268
- OpenAlex
- W2168949724
- Cited by
- 44
- References
- 9
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase. https://app.cochat.ai/papers/10.1161/circgenetics.113.000395
- The paper
- Dubé, M.-P., Zetler, R., Barhdadi, A., Brown, A. M. K., Mongrain, I., Normand, V., Laplante, N., Asselin, G., Zada, Y. F., Provost, S., Bergeron, J., Kouz, S., Dufour, R., Diaz, A., de Denus, S., Turgeon, J., Rhéaume, E., Phillips, M. S., & Tardif, J.-C. (2014). CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase. Circulation: Cardiovascular Genetics. https://doi.org/10.1161/circgenetics.113.000395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.